Clinical trial
A Multicenter, Phase I/II Trial of Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast Cancer
NCT03304080 is registered in ClinicalTrials.gov with Icahn School of Medicine at Mount Sinai as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Phase I/II Trial of Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast Cancer
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Phase
- Phase 1/2
- Overall status
- Active, not recruiting
- Start date
- December 20, 2017
- Completion date
- December 31, 2027
- Enrollment
- 44 (actual)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.